Reports Q4 revenue $1.26B, consensus $1.25B. “2025 was another great year for Dexcom (DXCM) as we significantly expanded access to Dexcom CGM and launched our Dexcom G7 15 Day System,” said Jake Leach, Dexcom’s president and CEO. “We look forward to building on this momentum in 2026 as we work to deliver improved health outcomes for many more people globally.”
Easter Sale - 70% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DXCM:
- Notable companies reporting after market close
- DXCM Earnings this Week: How Will it Perform?
- Largest borrow rate increases among liquid names
- Dexcom: Strong 2025 Outperformance, Durable CGM Growth Runway, and Upcoming Product Catalysts Support Buy Rating
- Dexcom: 2026 Reset Year Sets Stage for Renewed Growth and Upside Potential